Additional Monocyte analysis of samples from MOv18 IgE Phase I trial

• Research type

  Research Study

• Full title

  Effects of MOv18 IgE, a first in class chimeric IgE antibody against folate receptor-, on monocyte phenotype and function in collected patient PBMC samples from MOv18 IgE Phase Ia Clinical Trial

• IRAS ID

  329428

• Contact name

  Sophia N Karagiannis

• Contact email

  sophia.karagiannis@kcl.ac.uk

• Sponsor organisation

  Cancer Research UK

• Duration of Study in the UK

  1 years, 2 months, 1 days

• Research summary

  Therapeutic antibodies have significantly improved the prognosis of patients with a range of cancers. Currently available therapeutic antibodies belong to the IgG class. This study is looking at a new drug called MOv18 which belongs to a different class of antibody, the IgE class. IgE antibodies may trigger a more powerful immune response to tumour cells than these available IgG antibodies and so be more effective in treating certain types of cancer. This is the first time an IgE antibody therapy will be given to patients with cancer.
  MOv18 antibodies are designed to recognise and attach to a particular protein called folate receptor-alpha. Scientists have found more of this protein on the surface of certain cancer cells than on the surface of normal cells, most commonly ovarian cancer and to a lesser extent cancers of the kidney, pleura, endometrium, lung, breast, bladder, colon and pancreas. Once attached, the MOv18 IgE antibody should trigger the body’s own immune system to attack and kill the cancer cells.
  The Sponsor has previously conducted a Phase I clinical trial of the MOv18 IgE antibody in patients with advanced tumours expressing FRα. The Phase I trial was completed in 2021. This research study proposes to analyse remaining samples from the Phase I clinical trial in order to provide important insights into the immune response. This will inform further development and future studies of this antibody class.

• REC name

  London - Westminster Research Ethics Committee

• REC reference

  23/PR/0884

• Date of REC Opinion

  2 Nov 2023

• REC opinion

  Favourable Opinion